Sai Life Sciences working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
86.26×86.26×93.15×
60.63×60.63×76.42×
194.31×194.31×252.74×
−47.42×−47.42×−83.17×
3.90×3.80×2.19×
0.65×0.65×0.54×
1.46×1.46×1.85×
0.81×0.81×0.77×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SAILIFE₹1,395.00

Sai Life Sciences Ltd.

· Pharma & Health
₹ CrorePeersSYNGENEDIVISLABPPLPHARMANHNEULANDLABNATCOPHARMLALPATHLABCOHANCEMcap ₹29,543 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)93.1586.2686.26
Receivable Days (DSO)76.4260.6360.63
Payable Days (DPO)252.74194.31194.31
Cash Conversion Cycle (days)-83.17-47.42-47.42
Working Capital Turnover2.193.803.90
Asset Turnover0.540.650.65
Cash Conversion (CFO/Net Income)1.851.461.46
CFO/EBITDA0.770.810.81
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.